Abu Raihan Pharmaceutical Company

What Abu Raihan Pharmaceutical Company does

Abu Raihan Pharmaceutical Company (شرکت داروسازی ابوریحان) is an Iranian pharmaceutical manufacturer founded in 1964 as Berlimed Iran under German company Schering (later acquired by Bayer), renamed to its current brand in 1981, and listed on the Tehran Stock Exchange as a public joint-stock company since 1991. The company operates as a subsidiary of TPICO (Tamin Pharmaceutical Investment Holding), itself controlled by Iran's Social Security Organization (Shasta). Headquartered in Tehran with 500+ specialized personnel, Abu Raihan produces over 200 pharmaceutical products across three core lines: human pharmaceuticals (cardiovascular, neurological, endocrine, dermatological, women's health, allergy/immunology, respiratory, infectious diseases, anesthesia, pain management), veterinary pharmaceuticals (antibiotics, anti-inflammatory, anti-parasitic, hormonal, vitamins/minerals), and dietary supplements. The company is recognized as Iran's primary manufacturer of hormonal medicines, with production adhering to GXP, WHO, and GMP international standards, including ISO 14001:2015 and ISO 45001:2018 certifications.

The company's revenue model is based on one-time product sales through multiple channels: direct sales to Iranian hospitals and medical centers, distribution through Iran's pharmaceutical distribution network (notably Darpakhsh), and retail through pharmacies for both human and veterinary products. Dietary supplements are sold over-the-counter. The company also offers contract manufacturing services to other pharmaceutical firms. Export sales represent a growing revenue stream, with products shipped to Vietnam and Kurdistan Iraq, achieving 95% export growth in FY1404 and 5th national ranking among Iranian pharmaceutical exporters. Customer engagement mixes direct institutional sales outreach, participation in international pharmaceutical exhibitions (IranPharma Expo), and a content marketing asset (Health Magazine) on the company website.

The business operates under regulated pricing in Iran (prices set by healthcare authorities), with FY1404 demonstrating strong momentum: 95% export growth, 165% sales growth in one month, 118% of annual sales budget achieved in 9 months, and recent leadership reorganization under new CEO Dr. Seyed Hamidreza Mousavi (appointed January 2025). The company has received multiple national recognitions including the National Elite Unit title, 4-Star National Excellence and Progress Award (7th time), and Green Ecosystem Architects certification.

Name

Abu Raihan Pharmaceutical Company

Legal name

Abu Raihan Pharmaceutical Company (شرکت داروسازی ابوریحان)

Website

https://aburaihan.com

Company type

Public

Founded year

1964

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Abu Raihan Pharmaceutical Company is an Iranian pharmaceutical manufacturer founded in 1964, producing 200+ products across human medicines, veterinary pharmaceuticals, and dietary supplements. Recognized as Iran's primary hormonal medicines manufacturer, it serves hospitals, pharmacies, and export markets including Vietnam and Kurdistan Iraq.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid) (HLAMAEAG)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)

Keywords

• Pharmaceutical manufacturing
• Hormonal pharmaceuticals
• Veterinary medicines
• Dietary supplements
• Generic drug production

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Human Pharmaceutical Products: Sale of prescription and over-the-counter pharmaceutical products for human use across multiple therapeutic categories including cardiovascular, neurological, metabolic, dermatological, and women's health conditions.
2. Veterinary (Animal) Pharmaceutical Products: Production and sale of pharmaceutical products for animal health, distributed through Iran's veterinary pharmaceutical supply chain.
3. Dietary Supplements: Manufacturing and sale of dietary supplements for bone/joint health, cognitive function, cardiovascular health, energy, eye health, hair/nail/skin health, immune support, men's health, mood/stress/sleep, weight management, and women's health.
4. Contract Manufacturing: Company offers contract manufacturing services for pharmaceutical products under its production facilities.
5. International/Export Sales: Export of pharmaceutical products to international markets including Vietnam (hormonal products) and Kurdistan Iraq. Achieved 95% export growth in 1404 fiscal year.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Abu Raihan Pharmaceutical Company manufactures and sells human pharmaceutical products, veterinary pharmaceutical products, and dietary supplements across more than 200 SKUs, with a recognized leading position in hormonal medicines in Iran. Products span cardiovascular, neurological, endocrine/metabolic, dermatological, gastrointestinal, women's health, allergy/immunology, respiratory, infectious diseases, anesthesia, and pain management categories, and are produced in compliance with GXP and WHO international standards. The company also offers contract manufacturing services and exports to international markets including Vietnam and Kurdistan Iraq.

Product overview

Abu Raihan Pharmaceutical Company operates as a pharmaceutical manufacturer with three core product lines: Human Pharmaceutical Products, Veterinary Pharmaceutical Products, and Dietary Supplements. The company produces more than 200 types of drugs, with particular expertise in hormonal medications where it holds a leading market position in Iran. Human products span therapeutic categories including cardiovascular, neurological, endocrine/metabolic, dermatological, gastrointestinal, women's health, allergy/immunology, respiratory, infectious diseases, anesthesia, and pain management. The company also manufactures urea-based topical skincare products under its own brand. Production adheres to international GXP and WHO standards.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Pharmaceutical Products (محصولات انسانی) Broad portfolio of human pharmaceutical drugs covering therapeutic categories including cardiovascular, neurological, endocrine, dermatological, gastrointestinal, women's health, allergy/immunology, respiratory, infectious diseases, anesthesia, and pain management medications. Sold through pharmacies, hospitals, and medical centers across Iran.
• Veterinary Pharmaceutical Products (محصولات دامی) Veterinary pharmaceutical products including antibiotics, local anesthetics, anti-inflammatory, anti-parasitic, hormonal, vitamins and minerals for animal health applications. GMP-certified for veterinary injectable production by Iran's Veterinary Organization.
• Dietary Supplements (مکمل‌ها) Nutritional supplements covering bone/joint/muscle health, brain/cognitive function, cardiovascular health, energy/vitality, eye health, hair/nail/skin health, immune system/antioxidants, men's health, mood/stress/sleep, weight management, and women's health. Distributed through pharmacies and retail channels.
• Urea Cream (کرم اوره) Urea-based topical creams available in 5%, 10%, and 20% concentrations for skin moisturization, keratolytic effects, and treatment of dry skin, calluses, and cracked heels. Branded skincare product under the Abu Raihan name.
• Contract Manufacturing Services (تولید قراردادی) Contract manufacturing services offered to pharmaceutical companies using Abu Raihan's production facilities, GXP/WHO-compliant infrastructure, and quality systems. Leverages the company's manufacturing capacity and regulatory certifications for third-party production.
• Hormonal Pharmaceuticals Product Line Specialized category of hormonal medications in which Abu Raihan is recognized as the leading producer in Iran. Spans women's health (contraception, menopause, infertility, PCOS), endocrine/metabolic disorders (thyroid, adrenal), and veterinary hormonal products. Key differentiator and area of strategic focus.

Quantifiable outcome

• 95% export growth in fiscal year 1404, reaching $2,088,988 USD in export sales
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered major, core and minor.

• Vietnamese Commercial DelegationmajorStrategic or Co-development Partner · 3 September 1404A commercial delegation from Vietnam met with Abu Raihan's management team (CEO Dr. Mousavi, production VP Dr. Kabiri, and export sales manager) to explore joint cooperation in exporting specialized and hormonal medicines to the Vietnamese pharmaceutical market, with the goal of facilitating registration and entry of Abu Raihan products into Vietnam's healthcare network.
• Darpakhsh Distribution Company (پخش داروپخش)coreChannel Partner/ Reseller/ DistributorDarpakhsh is one of Iran's largest pharmaceutical distribution companies, serving as a key channel partner for distributing Abu Raihan's products to pharmacies and hospitals nationwide.
• Bayer AG (formerly Schering AG)minorOthersOriginally established in 1964 (1343 SH) as Berlimed Iran under ownership of German company Schering AG (acquired by Bayer in 2006). The company was renamed to Abu Raihan Pharmaceutical in 1981 (1360 SH).
• Kurdistan Iraq Pharmaceutical ImportersmajorChannel Partner/ Reseller/ DistributorAbu Raihan signed a significant export partnership agreement with Kurdistan Regional Government of Iraq at the IranPharma Expo exhibition, expanding its footprint in the Iraqi pharmaceutical market.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Regional players

• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers with broad human pharma portfolios across MENA. Comparable as a regionally-positioned generic/specialty pharma peer with similar export ambitions across the Middle East.
• Julphar (Gulf Pharmaceutical Industries): UAE-based generic pharmaceutical manufacturer serving MENA markets with broad human pharma portfolios. Comparable as a regional player with similar generic/specialty mix targeting Middle East and Islamic markets — overlapping with Abu Raihan's export ambitions in Iraq and beyond.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Leading Saudi Arabian pharmaceutical manufacturer with broad human pharma portfolio across cardiovascular, endocrine, and specialty categories. Comparable as a regional pharmaceutical peer operating in the same MENA regulatory and distribution environment.

Broad incumbents

• Bayer AG: Global pharmaceutical and life sciences giant and Abu Raihan's historical foreign owner (via Schering AG, acquired 2006). Bayer's specialty pharmaceutical franchise — especially in women's health and hormonal therapies — overlaps directly with Abu Raihan's core competency.
• TPICO (Tamin Pharmaceutical Investment Holding): Abu Raihan's direct parent holding company, TPICO consolidates multiple Iranian pharma manufacturers and serves as a broad incumbent across the industry. Comparable as the corporate umbrella that shapes Abu Raihan's strategy and channel access.

Direct peers

• CinnaGen Pharmaceutical Company: Leading Iranian biopharmaceutical manufacturer focused on biosimilars, biotech drugs, and specialty therapies. Comparable as an Iranian pharma competitor with R&D-driven specialty positioning.
• Barekat Pharmaceutical Group: Major Iranian pharmaceutical manufacturer with broad human pharma, biotech, and consumer health portfolios. Competes directly with Abu Raihan across multiple therapeutic categories in the same regulated domestic market.
• Sobhan Oncology: TPICO-affiliated Iranian pharma specializing in oncology and specialty therapeutics. Operates within the same TPICO holding umbrella as Abu Raihan with overlapping regulatory and distribution infrastructure.
• Darou Pakhsh Pharma Manufacturing Company: Iran's largest pharmaceutical manufacturer and Abu Raihan's sister company under TPICO Holding. Both produce a broad human and veterinary pharma portfolio serving the same domestic distributors and hospitals — the most directly comparable Iranian pharma peer.
• Exir Pharmaceutical Company: Iranian pharmaceutical manufacturer also operating under TPICO's ecosystem, producing generic human medicines. Directly comparable product portfolio and distribution footprint to Abu Raihan within Iran.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Aburaihanpharma
• Facebookfacebook.com/Aburaihanpharma
• LinkedInlinkedin.com/company/aburaihanpharma

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abu Raihan Pharmaceutical Company